CIK 0001774857 · <br>Emerging growth company
Aardvark Therapeutics, Inc.
Sign in to watch- Ticker
- AARD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821606367
- Phone
- (858) 225-7696
- Business address
- 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $394,957
- in 1 filing, $395K under 10b5-1 plans
Net −$394,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd 10% owner | Conversion · Series A Convertible Preferred Stock | −13,875,429 | 0 | ||
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd 10% owner | Conversion · Series B Convertible Preferred Stock | −3,503,919 | 0 | ||
| 2025-02-14 | Lee Tien-Li Chief Executive Officer | Conversion | +41,303 | 1,479,633 | ||
| 2025-02-14 | Lee Tien-Li Chief Executive Officer | Purchase | +16,542 | $16.00 | $265K | 1,496,175 |
| 2025-02-14 | Lee Tien-Li Chief Executive Officer | Conversion · Series A Convertible Preferred Stock | −350,002 | 0 | ||
| 2025-02-14 | Sun Nelson Chief Financial Officer | Conversion | +7,001 | 89,484 | ||
| 2025-02-14 | Sun Nelson Chief Financial Officer | Purchase | +10,000 | $16.00 | $160K | 99,484 |
| 2025-02-14 | Sun Nelson Chief Financial Officer | Conversion · Series C Convertible Preferred Stock | −59,332 | 0 | ||
| 2025-02-14 | Cormorant Asset Management, LP Former 10% Owner | Conversion | +800,189 | 800,189 | ||
| 2025-02-14 | Cormorant Asset Management, LP Former 10% Owner | Purchase | +187,500 | $16.00 | $3.0M | 987,689 |
| 2025-02-14 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series C Convertible Preferred Stock | −6,780,810 | 0 |
Page 4 of 4 · 71 trades